A well-structured CCS demonstrates to regulators that your organization takes contamination control seriously, understands its risks, and proactively manages them.
- EU Annex 1 Compliance – Annex 1 requires every manufacturer of sterile medicinal products to establish and maintain a formal CCS that holistically addresses contamination prevention.
- FDA Expectations – While the FDA does not require a formal CCS document, the same elements must be addressed in alignment with the 2004 aseptic processing guidance. Presenting this information in a structured CCS demonstrates preparedness and a mature quality culture.
By integrating your CCS into your overall Quality Management System (QMS), you strengthen both regulatory readiness and operational performance.
While not mandated, the FDA’s aseptic processing guidance (2004) expects this information. Even if the product is not sterile, contamination can make it adulterated under federal law. A CCS shows regulators you are prepared and take contamination control seriously.















